Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cardiff Oncology Inc is a biotechnology business based in the US. Cardiff Oncology shares (CRDF) are listed on the NASDAQ and all prices are listed in US Dollars. Cardiff Oncology employs 22 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $2.20 |
|---|---|
| 52-week range | $1.13 - $8.58 |
| 50-day moving average | $1.51 |
| 200-day moving average | $4.05 |
| Wall St. target price | $12.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.84 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.2 from 2022-06-30
| 1 week (2022-06-24) | -3.08% |
|---|---|
| 1 month (2022-06-01) | 78.86% |
| 3 months (2022-04-01) | -11.65% |
| 6 months (2021-12-31) | -63.39% |
| 1 year (2021-07-01) | -66.92% |
|---|---|
| 2 years (2020-07-01) | -53.78% |
| 3 years (2019-07-01) | 2.52 |
| 5 years (2017-06-30) | 74.60% |
| Revenue TTM | $361,000 |
|---|---|
| Gross profit TTM | $-17,017,000 |
| Return on assets TTM | -16.04% |
| Return on equity TTM | -26.76% |
| Profit margin | 0% |
| Book value | $3.00 |
| Market capitalisation | $99.2 million |
TTM: trailing 12 months
We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.
Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.
Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $1.13 up to $8.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 2.0304. This would suggest that Cardiff Oncology's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.